<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Plasma cytokine and chemokine concentrations in baseline, 6-month follow-up and repeat episodes of syphilis (pg/ml)</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th/>
    <th>Baseline infection</th>
    <th>6 month</th>
    <th>Repeat infection</th>
    <th>
     <italic>P</italic>-Value
     <sup>a</sup>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>IFNα</td>
    <td>12.1 (1.6–24.2)</td>
    <td>0.8 (0.8–2.6)</td>
    <td>0.8 (0.8–0.8)</td>
    <td>0.004</td>
   </tr>
   <tr>
    <td>IFNγ</td>
    <td>1.5 (1.5–8.9)</td>
    <td>1.7 (1.5–10.3)</td>
    <td>1.54 (1.5–10.6)</td>
    <td>0.714</td>
   </tr>
   <tr>
    <td>IL1β</td>
    <td>1.5 (1.5–1.5)</td>
    <td>1.57 (1.5–1.5)</td>
    <td>1.57 (1.5–1.5)</td>
    <td>.</td>
   </tr>
   <tr>
    <td>IL12p40</td>
    <td>1.0 (1.0–1.0)</td>
    <td>1.0 (1.0–1.0)</td>
    <td>1.0 (1.0–1.0)</td>
    <td>.</td>
   </tr>
   <tr>
    <td>IL12p70</td>
    <td>1.6 (1.6–1.6)</td>
    <td>1.6 (1.6–1.6)</td>
    <td>1.6 (1.6–1.6)</td>
    <td>.</td>
   </tr>
   <tr>
    <td>IP-10</td>
    <td>855.4 (372.7–1143.6)</td>
    <td>672.9 (602.6–941.6)</td>
    <td>626.3 (462.0–740.4)</td>
    <td>0.424</td>
   </tr>
   <tr>
    <td>MCP-1</td>
    <td>242.1 (212.8–303.1)</td>
    <td>278.37(259.2–312.2)</td>
    <td>260.7 (225.8–294.0)</td>
    <td>0.533</td>
   </tr>
   <tr>
    <td>CCL3</td>
    <td>1.6 (1.6–4.9)</td>
    <td>1.6 (1.6–1.6)</td>
    <td>1.6 (1.6–1.6)</td>
    <td>0.127</td>
   </tr>
   <tr>
    <td>CCL4</td>
    <td>17.5 (4.9–32.8)</td>
    <td>12.4 (3.5–16.6)</td>
    <td>0.9 (0.9–12.1)</td>
    <td>0.022</td>
   </tr>
   <tr>
    <td>IL-4</td>
    <td>1.6 (1.6–1.6)</td>
    <td>1.6 (1.6–1.6)</td>
    <td>1.6 (1.6–1.6)</td>
    <td>.</td>
   </tr>
   <tr>
    <td>IL-5</td>
    <td>1.6 (1.6–1.6)</td>
    <td>1.6 (1.6–1.6)</td>
    <td>1.6 (1.6–1.6)</td>
    <td>.</td>
   </tr>
   <tr>
    <td>IL-6</td>
    <td>1.3 (1.3–1.3)</td>
    <td>1.3 (1.3–1.3)</td>
    <td>1.3 (1.3–1.3)</td>
    <td>.</td>
   </tr>
   <tr>
    <td>IL-7</td>
    <td>1.1 (1.1–1.6)</td>
    <td>1.1 (1.1–1.1)</td>
    <td>1.1 (1.1–1.1)</td>
    <td>.</td>
   </tr>
   <tr>
    <td>IL-8</td>
    <td>2.5 (1.6–5.6)</td>
    <td>1.6 (1.6–4.1)</td>
    <td>2.1 (1.6–2.4)</td>
    <td>0.265</td>
   </tr>
   <tr>
    <td>IL-10</td>
    <td>1.5 (1.5–31.5)</td>
    <td>3.3 (1.9–8.4)</td>
    <td>1.8 (1.8–1.9)</td>
    <td>0.787</td>
   </tr>
   <tr>
    <td>IL-17A</td>
    <td>1.5 (1.5–1.5)</td>
    <td>1.5 (1.5–1.5)</td>
    <td>1.5 (1.5–1.5)</td>
    <td>0.489</td>
   </tr>
   <tr>
    <td>RPR titre</td>
    <td>128 (64–128)</td>
    <td>8 (2–16)</td>
    <td>32 (16–128)</td>
    <td>0.07</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>All values are median and interquartile range</p>
  <p>
   <sup>a</sup> P-value is for paired comparison of reinfections with baseline infections (Wilcoxon’s signed rank test)
  </p>
 </table-wrap-foot>
</table-wrap>
